MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC
Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.
1 - 20 . (canceled)
21 . A method for reversing anergy in one or more anergic lymphocytes in a subject in need thereof, comprising administering a MYC fusion peptide to the subject, wherein the fusion peptide comprises:
(i) a transporter peptide sequence; and
(ii) a MYC polypeptide sequence.
22 . The method of claim 21 , wherein the MYC fusion peptide has Formula (I):
transporter peptide sequence-MYC polypeptide sequence.
23 . The method of claim 21 , wherein the MYC fusion peptide has Formula (II):
transporter peptide sequence-X-MYC polypeptide sequence, wherein -X- is a molecule that links the transporter peptide sequence and the MYC polypeptide sequence.
24 . The method of claim 21 , wherein the MYC fusion peptide has Formula (II):
transporter peptide sequence-X-MYC polypeptide sequence, wherein X is at least one amino acid.
25 . The method of claim 21 , wherein the MYC fusion peptide decreases the amount of anergic lymphocytes in the subject.
26 . The method of claim 21 , wherein the one or more anergic lymphocytes comprises an anergic B cell or an anergic T cell.
27 . The method of claim 21 , wherein reversing anergy results in an accelerated primary immune response to an antigen, or an accelerated primary immune response in a subject receiving vaccination against an antigen.
28 . The method of claim 27 , wherein the antigen is from a virus selected from the group consisting of: hepatitis A, hepatitis B, polio; measles; mumps; rubella; diphtheria; pertussis; tetanus; influenza; varicella zoster virus; rotavirus; meningococcal; pneumonia; smallpox; cholera; bubonic plague; yellow fever; tuberculosis; and human papillomavirus.
29 . The method of claim 21 , where the MYC fusion peptide increases the rate at which a lymphocyte ends anergy.
30 . The method of claim 21 , wherein reversing anergy results in an increase in the expression of IgM, IgMa, IgMb, B220, CD21/35, CD23, CD24 (HSA), CD40, CD69, CD80 and/or CD86 (B7-2).
31 . The method of claim 21 , wherein the MYC fusion peptide is formulated for oral administration, parenteral administration, intranasal administration, buccal administration, rectal administration, or intravenous administration.
32 . The method of claim 21 , wherein the MYC fusion peptide is formulated for intramuscular or subcutaneous administration.
33 . The method of claim 21 , wherein the MYC fusion peptide is formulated for topical or transdermal administration.
34 . The method of claim 21 , wherein the MYC fusion peptide is formulated as a delayed release formulation or as an extended release formulation.